Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2018 Jan;10(1):70-74.
doi: 10.21037/jtd.2017.12.100.

Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?

Caroline Ong  1 , Sripal Bangalore  1
Affiliations
Editorial

Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?

Caroline Ong et al. J Thorac Dis. 2018 Jan.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest: Sripal Bangalore, MD, MHA: Advisory board/consultant for The Medicines Company, Abbott Vascular, Pfizer, Astra Zeneca, Merck, and Amgen. C Ong has no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Temporal trends in anticoagulant strategies for Percutaneous Coronary Interventions, 2009 to 2014. (A) Rates of anticoagulant use from Q3 2009 through Q4 2014 for patients presenting with NSTEMI. Reproduced with permission from Secemsky et al. Circ Cardiovasc Qual Outcomes 2017;10; (B) Vates of anticoagulant use from Q3 2009 through Q4 2014 for patients presenting with STEMI. Reproduced with permission from Secemsky et al. JACC Cardiovasc Interv 2016;9:2376-86.
Figure 2
Figure 2
Clustered ranking plot for major adverse cardiovascular event and bleeding outcomes for various anticoagulant strategies. The higher the SUCRA (surface under the cumulative ranking curve) values, the greater the efficacy for the corresponding outcome. The hypothetical ideal agent maximizes the outcomes for both ischemic and bleeding endpoints. Reproduced with permission from Bangalore et al., BMJ 2014;349:g6419. GPI, glycoprotein Iib/IIIa; SUCRA: surface under the cumulative ranking curve.
See this image and copyright information in PMC

Comment on

  • Bivalirudin versus Heparin Monotherapy in Myocardial Infarction.
    Erlinge D, Omerovic E, Fröbert O, Linder R, Danielewicz M, Hamid M, Swahn E, Henareh L, Wagner H, Hårdhammar P, Sjögren I, Stewart J, Grimfjärd P, Jensen J, Aasa M, Robertsson L, Lindroos P, Haupt J, Wikström H, Ulvenstam A, Bhiladvala P, Lindvall B, Lundin A, Tödt T, Ioanes D, Råmunddal T, Kellerth T, Zagozdzon L, Götberg M, Andersson J, Angerås O, Östlund O, Lagerqvist B, Held C, Wallentin L, Scherstén F, Eriksson P, Koul S, James S. Erlinge D, et al. N Engl J Med. 2017 Sep 21;377(12):1132-1142. doi: 10.1056/NEJMoa1706443. Epub 2017 Aug 27. N Engl J Med. 2017. PMID: 28844201 Clinical Trial.

References

    1. Verheugt FW, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv 2011;4:191-7. 10.1016/j.jcin.2010.10.011 - DOI - PubMed
    1. Bosch X, Marrugat J, Sanchis J. Platelet glycoprotein IIb/IIIa blockers during percutaneous coronary intervention and as the initial medical treatment of non-ST segment elevation acute coronary syndromes. Cochrane Database Syst Rev 2013;(11):CD002130. - PMC - PubMed
    1. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005;293:1759-65. 10.1001/jama.293.14.1759 - DOI - PubMed
    1. Kastrati A, Neumann FJ, Schulz S, et al. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction. N Engl J Med 2011;365:1980-9. 10.1056/NEJMoa1109596 - DOI - PubMed
    1. Bangalore S, Toklu B, Kotwal A, et al. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ 2014;349:g6419. 10.1136/bmj.g6419 - DOI - PMC - PubMed

LinkOut - more resources